Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Kura Oncology, Inc. (NASDAQ: KURA).

Full DD Report for KURA

You must become a subscriber to view this report.


Recent News from (NASDAQ: KURA)

Kura Oncology Announces Pricing of Public Offering of Common Stock
Kura Oncology Announces Pricing of Public Offering of Common Stock
Source: OTC Markets
Date: November, 04 2015 00:00
Kura Oncology Announces Launch of Public Offering of Common Stock
Kura Oncology Announces Launch of Public Offering of Common Stock
Source: OTC Markets
Date: October, 28 2015 00:00
Kura Oncology Appoints Thomas Malley to Board of Directors
Kura Oncology Appoints Thomas Malley to Board of Directors
Source: OTC Markets
Date: October, 14 2015 00:00
Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma
Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma
Source: OTC Markets
Date: September, 30 2015 00:00
Kura Oncology Cleared for Quotation on the OTCQB
Kura Oncology Cleared for Quotation on the OTCQB
Source: OTC Markets
Date: September, 16 2015 00:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2017-09-1311.1011.6512.1010.951,018,005
2017-09-1211.5511.1011.7010.85988,073
2017-09-1112.5511.6513.4510.804,547,971
2017-09-089.3511.8013.809.3020,286,638
2017-09-077.106.857.206.701,035,857

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1421,87834,29363.7973Short
2018-08-1322,61130,58673.9260Short
2018-08-1013,56917,80176.2261Short
2018-08-0918,58932,51357.1741Short
2018-08-0815,78031,83549.5681Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on KURA.


About Kura Oncology, Inc. (NASDAQ: KURA)

Logo for Kura Oncology, Inc. (NASDAQ: KURA)

Kura Oncology is a clinical stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor. The company s preclinical pipeline includes KO , an ERK inhibitor, and a menin MLL inhibitor program.

 

Contact Information

 

 

Current Management

  • Troy Edward Wilson / CEO
  • Heidi Henson / CFO
  • Anna Nadolski / IR
  • Troy Edward Wilson / Chairman
  • Faheem Hasnain /
  • Robert Hoffman / Director
    • Robert E. Hoffman has served as a member of our Board of Directors since September . Mr. Hoffman is CFO of AnaptysBio, a position he has held since July . Mr. Hoffman was the Senior Vice President, Finance and CFO of Arena Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, until July and has held other finance and accounting management roles at Arena since , except that from March to August , Mr. Hoffman served as Chief Financial Officer for Polaris Group, a privately held drug development company. Mr. Hoffman is currently a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company and Kura Oncology, Inc. a biopharmaceutical company. He also currently serves as a member of the Financial Accounting Standards Board s Small Business Advisory Committee and the steering committee of the Association of Bioscience Financial Officers. In addition, Mr. Hoffman is a member and a former director and President of the San Diego Chapter of Financial Executives International. Mr. Hoffman holds a B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. inactive in the State of California.
  • Thomas Malley /

Current Share Structure

  • Market Cap: $568,682,443 - 05/17/2018
  • Authorized: 200,000,000 - 08/27/2015
  • Issue and Outstanding: 33,353,809 - 03/09/2018

 


Recent Filings from (NASDAQ: KURA)

OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: August, 27 2015

 

 


Daily Technical Chart for (NASDAQ: KURA)

Daily Technical Chart for (NASDAQ: KURA)


Stay tuned for daily updates and more on (NASDAQ: KURA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: KURA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in KURA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of KURA and does not buy, sell, or trade any shares of KURA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/